Efficacy and Safety of IPG11406 in Moderately to Severely Active Ulcerative Colitis (Phase 2)

NCT07535489 | Not Yet Recruiting Phase 2 FDA Drug

• 1 other identifier: IPG11406-C003
• Study Type: interventional
• Target: 144
• Locations: 1 country
• Sites: 1

Brief Summary

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and pharmacokinetics of IPG11406, an investigational oral drug, in adult patients with moderately to severely active ulcerative colitis (UC). UC is a chronic inflammatory bowel disease that causes long-term inflammation and ulcers in the colon, leading to symptoms like frequent diarrhea, rectal bleeding, abdominal pain, and urgent bowel movements. IPG11406 works by targeting the GPR183 receptor, which helps reduce immune cell migration to the inflamed colon, potentially easing UC symptoms and promoting mucosal healing. In this study, 144 eligible adult patients will be randomly assigned (1:1:1:1) to receive one of three doses of IPG11406 (10 mg, 20 mg, or 40 mg, taken twice daily by mouth) or a matching placebo for 12 weeks. Neither the patients nor their study doctors will know who is receiving the active drug or placebo to ensure unbiased results. The main goal of the study is to see how well IPG11406 works to achieve clinical remission (reduced or no UC symptoms) at 12 weeks, measured by the modified Mayo Score. Additional goals include evaluating other efficacy measures (such as clinical response, endoscopic remission, and histological improvement), long-term safety, how the drug is absorbed and processed in the body (pharmacokinetics), and changes in inflammatory biomarkers like fecal calprotectin and hsCRP. All participants will undergo regular study visits for safety assessments, including physical exams, laboratory tests, colonoscopies, and monitoring for any side effects throughout the 12-week treatment period and a 2-week follow-up. This study will help determine the optimal dose of IPG11406 for future larger clinical trials in UC patients.

Conditions

Moderately to Severely Active Ulcerative Colitis (UC)

Outcome Measures

Primary Outcomes (1)

• Proportion of participants achieving clinical remission at Week 12, as assessed by the modified Mayo Score (mMS)

  Clinical remission: mMS ≤2 with all subscores ≤1; stool frequency subscore 0 or 1 and ≥1 point decrease from baseline; rectal bleeding subscore 0; modified Mayo endoscopic subscore 0 or 1 (without friability for score 1)

  week 12

Secondary Outcomes (5)

• Proportion of participants achieving clinical response based on mMS at Week 12

  Week 12

• Proportion of participants achieving clinical response based on full Mayo Score at Week 12

  Week 12

• Proportion of participants achieving clinical remission based on full Mayo Score at Week 12

  Week 12

• Proportion of participants achieving combined PRO2 remission and endoscopic remission at Week 12

  Week 12

• Proportion of participants achieving endoscopic remission at Week 12

  Week 12

Study Arms (4)

IPG11406 10 mg BID

EXPERIMENTAL

Participants in this arm receive IPG11406 10 mg oral tablets twice daily (BID) for 12 weeks, in a double-blind, placebo-controlled design.

Drug: IPG11406

IPG11406 20 mg BID

EXPERIMENTAL

Participants in this arm receive IPG11406 20 mg oral tablets twice daily (BID) for 12 weeks, in a double-blind, placebo-controlled design.

Drug: IPG11406

IPG11406 40 mg BID

EXPERIMENTAL

Participants in this arm receive IPG11406 40 mg oral tablets twice daily (BID) for 12 weeks, in a double-blind, placebo-controlled design.

Drug: IPG11406

Placebo

PLACEBO COMPARATOR

Participants in this arm receive matching placebo oral tablets twice daily (BID) for 12 weeks, identical in appearance to IPG11406, to maintain the double-blind study design.

Drug: Placebo

Interventions

IPG11406 DRUG

This intervention refers to IPG11406, an investigational oral tablet being evaluated in a Phase 2, randomized, double-blind, placebo-controlled, dose-ranging study in adult patients with moderately to severely active ulcerative colitis (UC). IPG11406 is administered twice daily (BID) at three dose levels (10 mg, 20 mg, or 40 mg) for 12 weeks. The formulation is intended for oral administration, with matching placebo used as the control. The primary objective is to assess clinical remission based on the modified Mayo Score at Week 12. Secondary and exploratory endpoints include clinical response, endoscopic/histologic improvement, pharmacokinetics, safety, and changes in inflammatory biomarkers.

IPG11406 10 mg BID; IPG11406 20 mg BID; IPG11406 40 mg BID

Placebo DRUG

This intervention refers to matching placebo oral tablets, identical in appearance, shape, size, and color to the IPG11406 investigational product, used as the control in this Phase 2, randomized, double-blind, placebo-controlled study in adult patients with moderately to severely active ulcerative colitis. The placebo is administered twice daily (BID) for 12 weeks, following the same dosing schedule as the active IPG11406 treatment arms, to maintain the double-blind study design. It contains no active pharmaceutical ingredient (API) and is formulated to be indistinguishable from IPG11406 tablets for participants, investigators, and study staff.

Placebo

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may not qualify if:

• Diagnosis of indeterminate colitis or Crohn's disease
• History of bowel surgery for UC or likely requiring surgery during study
• Ulcerative proctitis only (distal ≤15 cm)
• History of colonic dysplasia or adenomatous polyps not completely removed
• Active intestinal infection (including C. difficile) within 30 days
• HBV, HCV, HIV, or untreated latent/active TB
• Significant cardiovascular disease or uncontrolled hypertension
• Clinically significant abnormal ECG or QTcF prolongation
• Treatment with prohibited medications within specified windows
• Abnormal laboratory values at screening
• History of malignancy (except non-melanoma skin cancer or in situ cervical cancer)
• Pregnancy, breastfeeding, or plan to become pregnant
• Alcohol or drug abuse within 6 months
• Prior participation in an IPG11406 study
• Other conditions deemed inappropriate by the investigator

Sponsors & Collaborators

• Nanjing Immunophage Biotech Co., Ltd: lead
• Peking Union Medical College: collaborator

Study Sites (1)

Peking Union Medical College Hospital Chinese Academy of Medical Sciences

Beijing, China

Location

Central Study Contacts

Filipe Huang

CONTACT

+86-21-34782827; yfhuang@immunophage.com.cn

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 10, 2026
• First Posted: April 17, 2026
• Study Start (Estimated): July 7, 2026
• Primary Completion (Estimated): December 1, 2028
• Study Completion (Estimated): December 1, 2029
• Last Updated: April 17, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)